Built from Pacific Biosciences of California, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$1.96-0.8%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Company outlook: revenue of $155M to $160M for Fiscal year 2026 — down 1.6% on a year earlier ($160M)
The themes Pacific Biosciences of California is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc$131.6BA+
SYKStryker Corp.$117.9BA+
EWEdwards Lifesciences Corporation$61.6BA+
GEHCGE Healthcare Technologies Inc.$37.5BA
GKOSGlaukos Corp$14.5BARose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher CorporationOct 21, 2026CBGraded C, now B
MCKMckesson CorporationNov 4, 2026BAGraded B, now A
CVSCVS Health CorpNov 4, 2026BAGraded B, now AEWEdwards Lifesciences CorporationNov 4, 2026BAGraded B, now AGEHCGE Healthcare Technologies Inc.Oct 28, 2026CAGraded C, now AJust reported
From Pacific Biosciences of California's results release of November 4, 2026; its quarterly report has since been filed.
Actual
$40.6M
+5.5% y/y
+4.0% q/q
Guided
—
No guide given
Actual
-$0.12
Guided
—
No guide given
Actual
-$37M
Guided
—
No guide given
Full year 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade F-
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 41 quarters of Pacific Biosciences of California, Inc.’s grade history. The other 39 go back to November 2016.